Novartis AG (NVS)
| Market Cap | 231.34B |
| Revenue (ttm) | 48.86B |
| Net Income (ttm) | 16.18B |
| Shares Out | 2.02B |
| EPS (ttm) | 7.84 |
| PE Ratio | 14.30 |
| Forward PE | 14.57 |
| Dividend | $3.78 (3.32%) |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 970,432 |
| Open | 114.59 |
| Previous Close | 113.95 |
| Day's Range | 113.73 - 114.66 |
| 52-Week Range | 92.19 - 120.92 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 120.25 (+5.61%) |
| Earnings Date | Oct 29, 2024 |
About NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $120.25, which is an increase of 5.61% from the latest price.
News
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a tre...
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from...
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across multip...
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Dru...
Novartis not joining the 'frenzy' of weight loss drugs - CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with ...
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi...
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Basel, September 16, 2024 – In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqali® (ribociclib) added to endocrine therapy (ET) shows a deepening benefit beyond the ...
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Goldman Sachs has downgraded Novartis AG NVS, citing “limited value driving innovation catalysts in the near term.”
Cramer's Stop Trading: Novartis
CNBC's Jim Cramer explains why he is keeping an eye on shares of Novartis.
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
RALEIGH, N.C.--(BUSINESS WIRE)--Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive gl...
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy ac...
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Satur...
Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding
VANCOUVER--(BUSINESS WIRE)--Borealis Biosciences, a next-generation RNA medicines company, today emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ve...
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a ...
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the ...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. pla...
US FDA approves Novartis' kidney disease drug
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and devel...
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.
Novartis: Another Beat, Another Raise
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer ...
Why Novartis Deserves Your Attention After Q2 2024 Results
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year...